• Exosomal HMGB1 Drives Glomerular Endothelial Injury in Lupus

  2026-06-03

  This study reveals that podocyte-derived exosomes carrying HMGB1 mediate glomerular endothelial cell (GEC) injury in lupus nephritis by upregulating TRIM27 expression. The findings clarify a mechanistic pathway for endothelial dysfunction in LN and suggest that targeting exosome release or HMGB1 cargo could offer new therapeutic angles.

• Sodium Nitroprusside as a Nitric Oxide Donor in Vascular Res

  2026-06-03

  Sodium Nitroprusside enables precise dissection of vasodilation and platelet function, supporting advanced workflows in sex-difference hypertension research. This guide translates recent mechanistic insights into actionable protocols and troubleshooting tips, empowering researchers to maximize reproducibility and data quality.

• Synthetic Efferocytic Microglia Enable Anti-Inflammatory Aβ

  2026-06-02

  Shao et al. report a novel synthetic efferocytic receptor (SER) that reprograms microglia to selectively clear amyloid-β (Aβ) in Alzheimer’s disease (AD) mouse models without triggering proinflammatory responses. Their work demonstrates that in situ mRNA-mediated microglial engineering enhances Aβ phagocytosis, reduces neuroinflammation, and improves behavioral outcomes, providing a promising blueprint for immune-silent CNS therapies.

• Pazopanib (GW-786034): Precision Protocols for Cancer Resear

  2026-06-02

  Pazopanib (GW-786034) stands out as a multi-targeted RTK inhibitor enabling high-fidelity angiogenesis and tumor growth suppression, particularly in genetically defined cancer models. This guide translates the latest evidence and expert workflows into actionable protocols, troubleshooting steps, and advanced use-cases for researchers leveraging APExBIO’s trusted reagent.

• Erastin: Mechanistic Insights and Translational Frontiers in

  2026-06-01

  This article dissects the mechanistic underpinnings and translational opportunities of Erastin, a benchmark ferroptosis inducer, for cancer biology and drug resistance research. By integrating recent evidence on lipid metabolism, antioxidant pathways, and platinum resistance, it provides actionable guidance for researchers seeking to exploit ferroptosis vulnerabilities in tumor models. Practical protocol parameters, strategic considerations, and a forward-looking outlook are included, all anchored to the latest literature and product intelligence.

• LY2228820: Redefining p38 MAPK Inhibition for Translational

  2026-06-01

  This thought-leadership article offers a strategic deep dive into the mechanistic and translational implications of LY2228820, a highly selective p38 MAP kinase inhibitor. We connect rigorous molecular insights to real-world experimental protocols, anchor the discussion in the latest anti-inflammatory and anti-angiogenic research, and provide actionable guidance for researchers advancing preclinical and translational programs. By integrating evidence from recent multiomics studies and cross-referencing pioneering airway stent research, we illuminate how LY2228820 positions APExBIO as a driver of precision in inflammation and cancer research.

• Z-DEVD-FMK: Applied Caspase-3 Inhibitor Workflows in Apoptos

  2026-05-31

  Z-DEVD-FMK, a potent cell-permeable caspase-3 inhibitor from APExBIO, provides researchers with unparalleled precision in dissecting apoptotic and neuroprotective pathways. This guide offers detailed protocols, troubleshooting strategies, and practical insights to maximize reproducibility and impact across apoptosis and brain injury models.

• Linoleic Acid (C18:2): Mechanisms, Evidence, and Workflow Us

  2026-05-30

  Linoleic Acid is an essential omega-6 fatty acid and a key tool in cell-based oxidative stress and migration assays. Its mechanistic role in membrane fluidity, redox biology, and translational control is supported by recent translational research. This article provides protocol parameters, pitfalls, and evidence-backed claims for laboratory and preclinical use.

• Pexidartinib (PLX3397) for CSF1R-Mediated Tumor Macrophage M

  2026-05-29

  Pexidartinib (PLX3397) empowers cancer researchers to precisely modulate tumor-associated macrophages via selective CSF1R inhibition. This article explores optimized workflows, new experimental paradigms, and troubleshooting strategies for leveraging Pexidartinib in translational oncology, with practical guidance drawn from the latest reference breakthroughs.

• QPRT Drives Breast Cancer Invasion via P2Y11-Mediated Signal

  2026-05-29

  Liu et al. (2021) identify quinolinate phosphoribosyltransferase (QPRT) as a promoter of breast cancer cell invasiveness through phosphorylation of myosin light chain, implicating purinergic P2Y11 receptor signaling. These findings highlight QPRT and P2Y11 antagonism as mechanistically relevant targets for understanding and potentially modulating breast cancer progression.

• Pazopanib (GW-786034): Advancing Translational Oncology Insi

  2026-05-28

  This thought-leadership article explores the mechanistic rationale and translational promise of Pazopanib (GW-786034) as a multi-targeted RTK inhibitor in cancer research, with a special focus on ATRX-deficient glioma models. Synthesizing latest peer-reviewed evidence and strategic recommendations, it provides actionable guidance for translational researchers seeking to harness the full experimental and clinical potential of angiogenesis inhibition.

• Hematoxylin and Eosin Staining Kit: Protocol and QC Guidance

  2026-05-28

  The Hematoxylin and Eosin Staining Kit (SKU: K1142) provides standardized, ready-to-use solutions for efficient cellular and tissue morphology visualization in research settings. It streamlines histopathological and cytological staining workflows for paraffin and frozen sections, but is not suitable for diagnostic or clinical use.

• MG-132 (Z-LLL-al): Unraveling Proteasome Inhibition for Auto

  2026-05-27

  Explore the multifaceted scientific impact of MG-132 as a proteasome inhibitor in autophagy, oxidative stress, and cancer research. This article provides advanced mechanistic insight and practical guidance for experimental design, setting it apart from standard MG-132 overviews.

• ROS-Responsive Nanoplatform Repairs M1 Macrophages in Diabet

  2026-05-27

  This study introduces a hierarchically targeted, ROS-responsive hydrogel platform for treating diabetic periodontitis by selectively repairing mitochondrial dysfunction in M1 macrophages. The findings demonstrate significant reduction of inflammation and tissue damage, offering a mechanistically novel approach beyond conventional bacterial debridement.

• IWP-2 in Cancer and Immunology: Beyond Wnt Inhibition

  2026-05-26

  Explore the advanced applications of IWP-2 as a potent Wnt production inhibitor, uniquely positioned at the intersection of cancer research and immunological modulation. This article delivers deep mechanistic insight and practical protocol guidance for innovative scientists.

14522 records 1/969 page Next 12345 下5页 Last page